Whole-body integrated positron emission tomogra-phy/computed tomography (PET/CT) with [11C] -and 18F -labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer. 11C- and 18F-choline PET/CT are used successfully for restaging prostate cancer in patients with biochemical recurrence of disease after definitive therapy, and this correct diagnosis impacts subsequent management, such as consideration of salvage therapy for local recurrence or systemic treatment for metastatic disease. 11C- and 18F-choline PET/ CT have more limited roles for the initial staging of prostate cancer due to the low spatial resolution inherent to PET. Overall, these modalities are most useful in patients with a high pre-test suspicion of metastatic disease. The present review discusses the current role of 11C- and 18F-choline PET/CT in the management of prostate cancer, discussing its usefulness and limitations in the imaging of these patients.
|Original language||English (US)|
|Number of pages||10|
|Journal||Japanese Journal of Clinical Radiology|
|State||Published - Feb 2014|
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging